[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-locally-advanced-or-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-locally-advanced-or-metastatic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,39,75,103,128,151,187,211,258,284],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100641267","phase-2-a-clinical-trial-comparing-the-efficacy-and-safety-of-different-doses-of-bl0175-injection-in-treating-postmenopausal-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-locally-advanced-or-metastatic-breast-cancer-100641267",false,"NCT07658183","A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer","A Randomized, Open-Label, Multicenter Phase II Clinical Trial: Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer Patients","Inclusion Criteria:\n\n1. Voluntary participation in the trial, understanding the specific procedures of the trial, and willing to sign a written informed consent form.\n2. Age ≥ 18 years.\n3. HR positive, HER2 negative, with locally advanced or metastatic breast cancer in postmenopausal patients during or after endocrine therapy.\n4. The blood pregnancy test result during the screening period must be negative (if the postmenopausal state is caused by GnRH agonists).\n5. If the postmenopausal state is caused by GnRH agonists, the trial participants must agree to take effective contraceptive measures from the time of enrollment until at least 2 years after the last administration of the study treatment. For patients with breast cancer, the use of estrogen-based hormonal contraceptive methods (including hormone-type intrauterine devices) is not allowed, while the efficacy of progestin-based hormonal contraceptive methods is currently unclear. Effective contraceptive measures include: a. Complete abstinence (if it is their preferred regular lifestyle); b. Intrauterine device; c. Bilateral tubal ligation; d. The partner has undergone vasectomy and confirmed no sperm; e. Dual barrier method (male condom combined with cervical cap, vaginal diaphragm, or contraceptive sponge in combination with spermicidal agent).\n6. At least one measurable lesion exists.\n7. The Eastern Cooperative Oncology Group (ECOG) status score at screening must be ≤ 1.\n8. Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Participants with symptomatic central nervous system (CNS) metastases or cancerous meningitis;\n2. Have a history of other primary malignant tumors (except for participants who have been cured of skin basal cell carcinoma, skin squamous cell carcinoma, or cervical carcinoma in situ, and participants with other primary tumors that have no evidence of disease for 2 years or more and do not require treatment).\n3. Patients whose pericardial effusion, pleural effusion or ascites remain uncontrollable after intervention.\n4. Participants who have a history of allogeneic transplantation (including but not limited to allogeneic organ, bone marrow, or stem cell transplantation).\n5. A history of allergic to fulvestrant, or prone to allergic reactions (such as prone to angioedema, urticaria, asthma, rash, etc.).\n6. Severe cardiovascular or cerebrovascular diseases, including: Heart failure classified as New York Heart Association (NYHA) functional class III-IV (assessment only for patients with a history of heart disease), or left ventricular ejection fraction (LVEF) \\\u003C50% (if LVEF data are available); Uncontrolled ventricular arrhythmias: baseline QT interval corrected by Fridericia method (QTcF) \\> 480 ms, or congenital long QT syndrome; Myocardial infarction, severe or unstable angina, congestive heart failure, cerebrovascular accident (including transient ischemic attack), symptomatic pulmonary embolism, or other clinically significant thromboembolic events occurring within 6 months prior to the first administration of the investigational drug, or coronary artery bypass graft surgery performed within 6 months prior to the first administration of the investigational drug; Clinically symptomatic bradycardia as assessed by the investigator; Other clinically significant cardiovascular diseases that, in the opinion of the investigator, make the patient unsuitable for participation in the trial.\n7. Human immunodeficiency virus (HIV) infection or positive HIV antibody test at screening.\n8. Active hepatitis B (HBV DNA ≥2000 IU\u002FmL) or active hepatitis C (HCV RNA ≥200 IU\u002FmL). Additionally, eligible participants with hepatitis B or C must agree to receive antiviral treatment according to established guidelines; otherwise, they will not be enrolled.\n9. Active infection requiring intravenous antibiotic therapy within 1 week prior to the first administration of the investigational drug.\n10. Moderate or severe hepatic impairment, defined as meeting Child-Pugh classification criteria B or C.\n11. Insufficient organ function reserve at baseline, as defined by any of the following criteria (no blood products \\[including platelets or red blood cells\\] or colony-stimulating factors \\[including granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or recombinant erythropoietin\\] administered within 7 days prior to testing): Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL; Total bilirubin \\>1.5×ULN; ALT or AST \\>3×ULN if no liver metastasis is present; ALT or AST \\>5×ULN if liver metastasis is present; Hemoglobin (Hb) \\\u003C90 g\u002FL; Platelet count (PLT) \\\u003C100×10⁹\u002FL; International Normalized Ratio (INR) \\>1.5 (for patients on anticoagulant therapy, values within therapeutic range are acceptable); Creatinine clearance \\\u003C30 mL\u002Fmin.\n12. Receipt of anti-tumor drugs or investigational agents within the following time intervals prior to the first administration of the investigational drug: Anti-tumor endocrine therapy, targeted small-molecule therapy, or radiotherapy (except palliative radiotherapy or radiotherapy not involving the planned target lesion) ≤14 days or 5 half-lives (whichever is shorter); Chemotherapy ≤28 days or 5 half-lives (whichever is shorter); Immunotherapy or cell therapy (e.g., chimeric antigen receptor T-cell therapy) ≤28 days; other forms of cell therapy must be discussed with the investigator to determine eligibility; Monoclonal antibodies used for anti-tumor treatment ≤28 days; Traditional Chinese medicine with a clearly defined anti-tumor indication ≤14 days; Immunosuppressive therapy for any reason ≤7 days; All other investigational drugs or devices ≤28 days or 5 half-lives (whichever is shorter).\n13. Bleeding disorders (e.g., disseminated intravascular coagulation, deficiency of coagulation factors), or requiring long-term anticoagulant therapy (excluding antiplatelet therapy and low-dose warfarin or low-molecular-weight heparin).\n14. Severe vascular embolic events requiring medical or surgical intervention.\n15. Active autoimmune diseases requiring systemic treatment (including use of immunomodulatory agents, corticosteroids, or immunosuppressive drugs).\n\n    Note: Patients with hyperthyroidism\u002Fhypothyroidism are eligible for enrollment. Hormonal replacement therapy and symptomatic treatments (e.g., levothyroxine for adrenal or pituitary insufficiency, insulin, or physiologic corticosteroid replacement) are not considered forms of systemic therapy and are permitted.\n16. Received systemic corticosteroids within 4 weeks prior to the first administration of the investigational medicinal product (except low-dose corticosteroids, such as ≤20 mg prednisone per day or equivalent).\n17. Underwent major surgery within 4 weeks prior to the first administration of the investigational medicinal product, or planned to undergo major surgery during the study period.\n18. Currently pregnant or breastfeeding, or expected to become pregnant during the study period (from screening visit through 2 years after the last dose of study treatment).\n19. Not recovered from toxicity related to prior treatment (including prior immunotherapy) and\u002For complications from surgical interventions to a CTCAE v6.0 grade ≤1.\n\n    Note: Participants with stable chronic adverse events (≤grade 2) that are not expected to resolve spontaneously (e.g., peripheral neuropathy and alopecia) are allowed.\n20. Any other condition deemed unsuitable for participation in this trial by the investigator.","FEMALE","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The main questions it aims to answer are:\n\n1. Which dose level of BL0175 demonstrates the optimal ORR?\n2. What is the recommended phase 3 dose (RP3D) based on efficacy and safety data across the tested dose levels?",[26],"Breast Cancer (Locally Advanced or Metastatic)","NOT_YET_RECRUITING","2026-06-16",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":20},"2026-07-20",{"date":35,"type":20},"2028-05-31",{"name":37,"class":38},"Shanghai Best-Link Bioscience, LLC","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100640853","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-antitumor-activity-of-inv-6452-in-adult-patients-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hrher2--advancedmetastatic-breast-cancer-or-locally-advancedmetastatic-solid-tumor-100640853","NCT07612891","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+\u002FHER2-) Advanced\u002FMetastatic Breast Cancer or Locally Advanced\u002FMetastatic Solid Tumor","A Phase 1 and Phase 2, First-in-Human, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+\u002FHER2-) Advanced\u002FMetastatic Breast Cancer or Locally Advanced\u002FMetastatic Solid Tumor","Inclusion Criteria:\n\n1. Written informed consent obtained.\n2. Adult patients aged ≥ 18 years.\n3. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+\u002FHER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors).\n4. Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).\n5. Have RECIST 1.1-defined measurable lesions.\n6. Has a life expectancy of \\> 3 months.\n7. ECOG performance status 0-1.\n8. Adequate marrow, liver and kidney function.\n9. Meet the study's specified contraceptive requirements.\n\nExclusion Criteria:\n\n1. Have a second primary malignancy.\n2. Patients with primary CNS tumors or CNS metastases with prior local treatment failure.\n3. Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.\n4. Has undergone major surgery within 28 days prior to the first dose of study drug.\n5. Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades.\n6. Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.\n7. Patients with other severe and persistent underlying medical conditions as assessed by the Investigator.\n8. Have protocol-defined clinically significant cardiovascular diseases.\n9. Prolonged QTcF interval.\n10. Have any medical conditions likely to impair digestion and absorption of the investigational product.\n11. Patients with poorly managed blood glucose levels and blood pressure.\n12. Clinically significant abnormal serum potassium or sodium as judged by the investigator.\n13. Have experienced a severe concurrent infection 14 days prior to the first dose of study drug.\n14. Confirmed infection with HIV, HBV or HCV.\n15. Are currently receiving any other investigation agent.\n16. Have received prior CDK2 inhibitors.\n17. Patients with known hypersensitivity to the study drug or any of its components.\n18. History of allogenic tissue or solid organ transplant.\n19. Are unwilling or unable to comply with procedures required in this protocol.\n20. Has other severe systemic diseases or for other reasons deemed ineligible for participation in this clinical trial by the investigator.","ALL",{"count":48,"type":20},201,[50,23],"PHASE1","This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+\u002FHER2-) advanced\u002Fmetastatic breast cancer or locally advanced\u002Fmetastatic solid tumor.",[26,53,54,55,56],"Advanced Solid Cancers","Metastatic (Stage IV) Breast Cancer","Ovarian Cancer","Endometrial Cancer",[58,59,60,61,62,63],"breast cancer","locally advanced solid tumor","metastatic solid tumor","ovarian cancer","endometrial cancer","HR+\u002FHER2-","RECRUITING","2026-05-27",{"date":67,"type":31},"2026-05-29",{"date":69,"type":31},"2025-07-04",{"date":71,"type":20},"2028-02-04",{"name":73,"class":38},"Shenzhen Ionova Life Sciences Co., Ltd.",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":46,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":74},"100621759","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-breast-cancer-100621759","NCT07374796","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient of UMMS\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at UMMS\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English",true,{"count":83,"type":20},450,"OBSERVATIONAL","The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[26,87,88,89],"Healthy Volunteers (HV)","Unhealthy Volunteers","Breast Cancer Screening",[91,89,92,88],"Breast Cancer","Healthy Volunteers","2026-04-21",{"date":95,"type":31},"2026-04-22",{"date":97,"type":20},"2026-06-01",{"date":99,"type":20},"2032-07",{"name":101,"class":102},"University of Maryland, Baltimore","OTHER",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":46,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":74},"100635506","remote-monitoring-and-symptom-management-digital-application-100635506","NCT07553572","Remote Monitoring and Symptom Management Digital Application","Pilot Randomized Controlled Trial of a Remote Monitoring and Symptom Management Intervention (ASSIST) Among Patients Receiving Systemic Therapy","ASSIST","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Ability to understand English\n3. About to begin definitive systemic treatment (or within 4 weeks of beginning treatment) based upon the oncology treatment intent form for a new diagnosis of breast cancer, colorectal cancer, or lymphoma.\n4. Expected treatment duration of at least 12 weeks\n5. Own or willing to receive a smartphone\n\nExclusion Criteria:\n\n1. Cognitive impairment that would interfere with ability to use smartphone application (as assessed by their attending physician)\n2. Visual or motor impairment that would prevent smartphone use\n3. Expected survival less than 3 months",{"count":112,"type":20},60,[114],"NA","The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment.\n\nThe main question\\[s\\] it aims to answer are:\n\nIs ASSIST feasible for patients (meaning can it be used by patients)? Is ASSIST acceptable to patients (meaning do patients like it)?\n\nResearchers will compare the ASSIST phone application to see how it compares to usual clinical care.\n\nParticipants on the ASSIST arm will use the ASSIST phone application for 12 weeks, and participants in both groups will complete surveys.",[26,117,118],"Lymphoma","Colorectal Cancer","2026-04-20",{"date":121,"type":31},"2026-04-28",{"date":123,"type":31},"2026-04-14",{"date":125,"type":20},"2027-03-31",{"name":127,"class":102},"Patrick C. Johnson, MD",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":46,"minAge":4,"maxAge":4,"enrollmentInfo":135,"targetDuration":137,"studyType":84,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100633194","diagnostic-performance-of-18f-fdg-petct-in-detecting-distant-metastases-in-breast-cancer-100633194","NCT07523516","Diagnostic Performance of 18F-FDG PET\u002FCT in Detecting Distant Metastases in Breast Cancer","Diagnostic Performance of F18-FDG PET\u002FCT in Detecting Distant Metastases in Breast Cancer","1. Inclusion criteria:\n\n   1. Patients with pathologically proven breast cancer\n   2. Metastatic breast cancer proved by pathology or radiological modalities.\n   3. Interval between 18F-FDG PET\u002FCT and CE-CT from one to three weeks.\n2. Exclusion criteria:\n\n   1. Patients with known concomitant malignancy\n   2. Patients receive systemic treatment chemotherapy or radiotherapy between 18F-FDG PET\u002FCT and CE-CT.",{"count":136,"type":20},97,"12 Months","compare the accuracy and sensitivity of 18F FDG-PET\u002FCT and CE-CT in detecting distant metastases in breast cancer",[26],[141],"breast cancer, metastatic, CE-CT","2026-04-05",{"date":144,"type":31},"2026-04-13",{"date":146,"type":20},"2026-04-01",{"date":148,"type":20},"2029-04-01",{"name":150,"class":102},"Assiut University",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":46,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":74},"100630316","phase-1-dual-target-car-nk-cells-for-advanced-breast-cancer-her2-and-tnbc-100630316","NCT07486089","Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","Phase 1\u002F2, Biomarker-guided, Open-label Study of Allogeneic Dual-target CAR-NK Cells Directed Against HER2\u002FERBB2, MUC1, and\u002For ROR1 in Patients With Advanced or Metastatic Breast Cancer (Including HER2-positive and Triple-negative Disease).","DUAL-NK-BC","Inclusion Criteria:\n\n* Histologically confirmed breast carcinoma that is locally advanced, unresectable, or metastatic.\n* Disease subtype: HER2-positive breast cancer or triple-negative breast cancer (TNBC).\n* Progression after, intolerance to, or ineligibility for standard therapies appropriate for the disease subtype and line of therapy.\n* At least one measurable lesion per RECIST v1.1.\n* Tumor antigen assessment available (fresh or archival): expression of at least one candidate target antigen (HER2\u002FERBB2, MUC1, or ROR1). For TNBC, mesothelin assessment may be performed for exploratory analyses.\n* ECOG performance status 0-1.\n* Adequate organ function (example thresholds): ANC ≥ 1.0 x 10\\^9\u002FL; platelets ≥ 75 x 10\\^9\u002FL; hemoglobin\n\n  * 8 g\u002FdL; AST\u002FALT ≤ 3x ULN (≤ 5x with liver metastases); total bilirubin ≤ 1.5x ULN; creatinine clearance\n  * 50 mL\u002Fmin.\n* Left ventricular ejection fraction (LVEF) ≥ 45% and no uncontrolled cardiac arrhythmia.\n* Negative pregnancy test for participants of childbearing potential; agreement to use effective contraception during study treatment and for 6 months after last CAR-NK infusion.\n* Ability to understand and willingness to sign informed consent.\n\nExclusion Criteria:\n\n* Active, untreated central nervous system (CNS) metastases or leptomeningeal disease. Patients with treated CNS metastases may be eligible if clinically stable for ≥ 4 weeks and off high-dose steroids.\n* Prior gene-modified cellular therapy (e.g., CAR-T or CAR-NK) within 6 months or unresolved grade ≥ 2 toxicity from prior cellular therapy.\n* Clinically significant active autoimmune disease requiring systemic immunosuppression (physiologic steroid replacement permitted).\n* Uncontrolled infection, including uncontrolled HBV, HCV, or HIV infection (controlled infections may be eligible per investigator).\n* History of severe hypersensitivity to fludarabine or cyclophosphamide.\n* Pregnant or breastfeeding.\n* Concurrent participation in another interventional study that could confound safety or efficacy assessments.\n* Any condition that, in the investigator's judgment, would make the participant unsuitable for the study (e.g., uncontrolled comorbidity, inability to comply with protocol procedures).","75 Years",{"count":112,"type":20},[50,23],"This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2\u002FERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.",[26,164,165],"HER2-positive Breast Cancer","Triple-Negative Breast Cancer (TNBC)",[167,168,169,170,171,172,173,174,175,176,177],"CAR-NK; dual targeting","doptive cellular immunotherapy","HER2 \u002F ERBB2","MUC1","ROR1","mesothelin","solid tumor","biomarker-guided cohort assignment","Lymphodepletion","fludarabine","cyclophosphamide","2026-03-17",{"date":180,"type":31},"2026-03-20",{"date":182,"type":31},"2026-02-02",{"date":184,"type":20},"2028-03-17",{"name":186,"class":38},"Beijing Biotech",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":74},"100629763","tumor-margin-skin-tattooing-before-neo-adjuvant-chemotherapy-in-patients-with-breast-cancer-100629763","NCT07478900","Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer","Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer: A Prospective Cohort Study","TUMS","Inclusion Criteria:\n\nFemale patients aged 18-75 years\n\nHistologically confirmed Breast Cancer on biopsy\n\nPatients with T2 or T3 breast tumors planned for Neoadjuvant Chemotherapy\n\nPresence of a clinically palpable primary breast tumor suitable for localization\n\nPatients who are candidates for Breast-Conserving Surgery following neoadjuvant therapy\n\nAbility and willingness to provide written informed consent\n\nExclusion Criteria:\n\nKnown allergy or hypersensitivity to tattooing materials used for tumor localization\n\nEarly-stage Breast Cancer not requiring Neoadjuvant Chemotherapy\n\nDiagnosis of Inflammatory Breast Cancer\n\nT3 tumors in patients with small breast size or T4 breast cancer\n\nPatients unwilling to undergo Breast-Conserving Surgery\n\nDiffuse microcalcifications of the breast parenchyma on Mammography\n\nDuctal Carcinoma In Situ\n\nMale Breast Cancer\n\nMulticentric or multifocal breast cancers\n\nTumor location that precludes breast-conserving surgery\n\nRecurrent Breast Cancer",{"count":196,"type":20},30,[114],"Study Description\n\nThis prospective cohort study evaluates the feasibility and effectiveness of pre-neoadjuvant tumor localization using skin tattooing, with or without radiopaque clips, in patients with biopsy-proven T2-T3 breast cancer and axillary lymph node metastasis. Eligible patients will undergo tumor localization in the supine position with the ipsilateral arm abducted to 90°. Palpable tumor margins will be marked with sterile tattoo ink, and deep or mobile tumors will receive additional localization with ultrasonography-guided radiopaque clips. Following localization, patients will receive standard neoadjuvant chemotherapy. Tumor response will be monitored clinically and radiologically. Post-therapy, the tattoo markings and\u002For clips will guide breast-conserving surgery. Primary outcomes include feasibility of breast conservation, achievement of negative margins (R0 resection), and avoidance of mastectomy, while intraoperative technical challenges will also be documented.",[26,200,201],"Tattoo Skin Markers","Neoadjuvant Chemoimmunotherapy","2026-03-14",{"date":204,"type":31},"2026-03-18",{"date":206,"type":31},"2025-09-10",{"date":208,"type":20},"2028-02-09",{"name":210,"class":102},"All India Institute of Medical Sciences, Bhubaneswar",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":46,"minAge":4,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":222,"conditions":223,"keywords":236,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":74},"100624518","phase-1-ebnk-001-allogeneic-nk-cells-with-low-dose-il-15--pembrolizumab-in-advanced-solid-tumors-100624518","NCT07410676","EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","An Open-Label Phase 1\u002F2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide\u002FFludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors","EBNK-ST-001","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed advanced\u002Fmetastatic solid tumor that is relapsed\u002Frefractory after standard therapy (or no standard therapy available).\n* Measurable disease per RECIST v1.1 (or iRECIST if applicable).\n* ECOG performance status 0-1 (or 0-2 as allowed).\n* Adequate organ function (thresholds modeled on NK protocols):\n* Platelets ≥ 75,000\u002FµL; hemoglobin ≥ 9 g\u002FdL; ANC ≥ 1,000\u002FµL (unsupported by growth factors\u002Ftransfusions as defined).\n* eGFR ≥ 60 mL\u002Fmin\u002F1.73m².\n* AST\u002FALT ≤ 3× ULN.\n* Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated).\n* LVEF ≥ 40% (by ECHO\u002FMUGA\u002FCMR).\n* If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Any condition requiring systemic immunosuppression (e.g., \\>5 mg prednisone\u002Fday or equivalent) during dosing window (topical\u002Finhaled may be allowed).\n* Active autoimmune disease requiring systemic immunosuppression.\n* Uncontrolled bacterial, fungal, or viral infection.\n* Receipt of investigational agent within 28 days before first study drug.\n* Live vaccine within 6 weeks prior to lymphodepletion.\n* Known HIV positivity or active hepatitis B\u002FC with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan).\n* Known allergy to investigational product components (example: albumin\u002Fhuman or DMSO).\n* Any medical\u002Fsocial condition likely to interfere with study compliance or increase risk.",{"count":220,"type":20},83,[50,23],"This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide\u002Ffludarabine (CY\u002FFLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced\u002Fmetastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.",[224,225,226,26,227,118,228,229,230,231,232,55,233,234,235],"Cancer","Sarcoma","Leukaemia","Lung Cancer (Diagnosis)","Melanoma (Skin Cancer)","Bladder Cancer","Kidney Cancer","Pancreatic Cancer Metastatic","Liver Cancer (Primary and Metastatic)","Esophageal Cancer","Glioblastoma","Non-Melanoma Skin Cancer",[237,238,239,240,91,241,242,243,244,235,245,229,246,247,248,233],"Natural killer cells","NK cell therapy","Solid tumors","IL-15","Lung and Bronchus Cancer","Prostate Cancer","Colorectal (Colon and Rectal) Cancer","CAR-T","Melanoma","Kidney (Renal Cell and Renal Pelvis) Cancer","Pancreatic Cancer","Stomach (Gastric) Cancer","2026-02-14",{"date":251,"type":31},"2026-02-18",{"date":253,"type":31},"2026-02-01",{"date":255,"type":20},"2029-12-21",{"name":257,"class":102},"Essen Biotech",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":46,"minAge":17,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":74},"100622993","phase-1-a-study-of-sh009-injection-in-patients-with-advanced-solid-tumors-100622993","NCT07390838","A Study of SH009 Injection in Patients With Advanced Solid Tumors.","An Open, Multicenter, Phase I Clinical Study on the Safety, Efficacy, and Pharmacokinetics of SH009 Injection in Patients With Advanced Solid Tumors.","Inclusion Criteria:\n\n* (1) Age≥18 years old at the time of informed consent, male or female;\n* (2) Subjects with histologically confirmed locally advanced, recurrent, or metastatic solid tumors (including but not limited to colorectal cancer, gastric cancer, hepatocellular carcinoma, head and neck cancer, breast cancer, non-small cell lung cancer, esophageal cancer, etc.) who have experienced disease progression or intolerance to at least one prior line of systemic therapy, and for whom no acceptable standard therapy exists or who cannot benefit from or tolerate standard therapy;\n* (3) Subjects must have at least one measurable lesion per RECIST 1.1 criteria. A lesion that has been previously irradiated can only be considered measurable if there is documented progression at that site following radiotherapy;\n* (4) Archival tumor tissue samples are available, or the subject agrees to undergo a tumor biopsy for the determination of PD-L1 and CD47 expression levels and other biomarker analyses;\n* (5) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2;\n* (6) Life expectancy ≥12 weeks;\n* (7) Bone marrow function meets the following criteria: neutrophil count ≥ 1.5 × 10\\^9\u002FL; platelet count ≥ 90 × 10\\^9\u002FL (platelet count ≥ 75 × 10\\^9\u002FL in patients with liver cancer); hemoglobin (Hb) ≥ 90 g\u002FL;\n* (8) Liver function meets the following criteria: total bilirubin(TBIL) ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN for subjects with Gilbert's syndrome); aspartate aminotransferase (AST) and alanine and aminotransferase (ALT) ≤ 3 × ULN (ALT and AST ≤ 5 × ULN for subjects with liver cancer or liver metastases);\n* (9) Renal function meets the following criteria: serum creatinine clearance(CLcr) ≥ 50 mL\u002Fmin (calculated according to Cockcroft-Gault formula); urine dipstick test results show that urine protein \\\u003C 2 +, urine protein ≥ 2 + subjects should undergo 24-hour urine collection and urine protein content \\\u003C 1g within 24 hours;\n* (10) Coagulation function meets the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5× ULN;\n* (11) Female subjects of childbearing potential must use effective contraception during the trial and for 6 months after the last dose, and have a negative pregnancy test within 7 days before treatment initiation (except those who are surgically sterilized or postmenopausal). Male subjects must agree to use effective contraception during the trial and for 6 months after the last dose;\n* (12) The subject is fully informed about this trial before its commencement and voluntarily signs and dates the informed consent form.\n\nExclusion Criteria:\n\n* (1) Prior exposure to any CD47 antibody, SIRPα antibody, or CD47\u002FSIRPα recombinant protein;\n* (2) Prior treatment with adoptive cellular therapies such as CAR-T, TCR-T, or TIL. Prior administration of an anti-cancer vaccine, or use of live or live-attenuated vaccines within 4 weeks prior to the first dose;\n* (3) Systemic anti-tumor therapies within the specified timeframes prior to the first dose of study drug: Chemotherapy, antibody-based targeted therapy, endocrine therapy, or immunotherapy within 3 weeks. Mitomycin or nitrosoureas within 6 weeks. Oral fluoropyrimidines (e.g., S-1, capecitabine) and small molecule targeted agents within 2 weeks or 5 half-lives of the drug (whichever is longer).Chinese\u002Fherbal medicines with anti-cancer activity indicated in their labeling must be discontinued prior to enrollment. Prior radical radiotherapy within 3 months before study drug administration is excluded. Palliative radiotherapy administered within 2 weeks prior to dosing is allowed if the dose meets local palliative care standards and the radiation field covers less than 30% of the bone marrow area;\n* (4) Received any investigational drug within 28 days before administration of this trial, or participated in another clinical study at the same time, except for the following circumstances: the patient participated in an observational, non-interventional clinical study, or was in the follow-up period after the end of treatment in an interventional clinical study but the drug withdrawal had exceeded the washout period;\n* (5) Had major organ surgery (excluding puncture biopsy) or had significant trauma within 4 weeks before the first administration, or needed to undergo elective surgery during the trial period;\n* (6) Patients who received systemic glucocorticoids (dexamethasone \\> 10 mg\u002F day or equivalent dose of the same drug) or other immunosuppressive therapy within 14 days before the first administration; except for topical, ocular, intra-articular, intranasal, and inhaled glucocorticoids; short-term use of glucocorticoids for prophylactic treatment (e.g., prevention of contrast allergy);\n* (7) Symptomatic brain parenchymal or leptomeningeal metastases, deemed by the investigator as unsuitable for enrollment;\n* (8) Prior immunotherapy with ≥Grade 3 irAE or ≥Grade 2 immune-related myocarditis;\n* (9) Severe or uncontrolled systemic disease, including but not limited to: uncontrolled pleural or peritoneal effusion; uncontrolled diabetes; ventricular arrhythmia requiring intervention; acute coronary syndrome, congestive heart failure, stroke, or other ≥Grade 3 cardiovascular event within 6 months; NYHA Class ≥II or LVEF \\\u003C50%; clinically significant QTcF prolongation or arrhythmia risk (baseline QTcF \\>450 msec for males or \\>470 msec for females); clinically uncontrolled hypertension (SBP \\>160 mmHg and\u002For DBP \\>90 mmHg after treatment) as judged by the investigator. Subjects judged by the investigator as unsuitable due to any such condition;\n* (10) History of pneumonia requiring hormone therapy or interstitial lung disease (including past and current history); active pulmonary infection;\n* (11) Active infection requiring intravenous anti-infective therapy within 1 week prior to study drug administration (fever attributed to the tumor per investigator's judgment is acceptable). History of self-limited infections that have resolved is acceptable;\n* (12) Active Hepatitis B, Hepatitis C, or syphilis infection. Subjects positive for HBeAb or HBsAg are eligible if HBV-DNA ≤200 IU\u002FmL. Subjects positive for HCV-Ab are eligible if HCV-RNA ≤ the upper limit of normal at the research center. Subjects with hepatocellular carcinoma and HBV-DNA ≥2000 IU\u002FmL must receive antiviral\u002Fhepatoprotective therapy first and can only enroll after HBV-DNA decreases to \\\u003C2000 IU\u002FmL;\n* (13) History of primary immunodeficiency, including positive human immunodeficiency virus (HIV) test, or suffering from other acquired, congenital immunodeficiency diseases;\n* (14) History of other malignancies within 5 years prior to the first dose, except for:\n\n  a) Any other invasive malignancy, treated with curative intent, with a disease-free interval \\>3 years and deemed by the investigator not to affect efficacy evaluation for the current tumor. b) Adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or other locally cured cancers;\n* (15) History or presence of autoimmune disease within 2 years, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis or high risk (e.g., post-transplant immunosuppression). Exceptions: stable type 1 diabetes on fixed-dose insulin; autoimmune hypothyroidism on hormone replacement only; skin conditions not requiring systemic treatment (e.g., eczema, rash covering\\\u003C10% BSA, psoriasis without ocular symptoms);\n* (16) Arterial thromboembolic events within 6 months prior to the first dose, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. History of deep vein thrombosis, pulmonary embolism, or other serious thromboembolism within 3 months prior to the first dose (catheter-related or superficial venous thrombosis is not considered \"serious\"). Receiving thrombolytic or anticoagulant therapy for high thrombotic risk;\n* (17) Subjects who had receive allogeneic hematopoietic stem cell transplantation or solid organ transplantation (except corneal transplant);\n* (18) According to CTCAE 5.0, adverse reactions from previous anti-tumor therapy have not yet returned to ≤ grade 1 (except for toxicities which are judged by researchers to be safe, such as hair loss, pigmentation, hypothyroidism stabilized by hormone replacement therapy and peripheral neuropathy (need to recover to ≤ grade 2)). Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the study drug may be allowed after consultation with the medical monitor;\n* (19) Known history of severe hypersensitivity to macromolecular protein preparations\u002Fmonoclonal antibodies(CTCAE v5.0 Grade ≥3), or any component of the study drug;\n* (20) Known alcohol and\u002For drug dependence, or any other condition deemed by the investigator to affect the safety or compliance of the study treatment, including but not limited to psychiatric disorders;\n* (21) Pregnant or lactating women.",{"count":266,"type":20},150,[50],"Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors",[270,271,272,26,233,273,274],"Liver Cancer (Locally Advanced or Metastatic)","Lung Cancer (NSCLC)","Head and Neck Cancer Squamous Cell Carcinoma","Gastric Cancer (GC)","Solid Tumor Malignancies","2026-01-28",{"date":277,"type":31},"2026-02-05",{"date":279,"type":31},"2025-05-16",{"date":281,"type":20},"2028-12-30",{"name":283,"class":38},"Nanjing Sanhome Pharmaceutical, Co., Ltd.",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":46,"minAge":17,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":293,"briefSummary":294,"conditions":295,"keywords":299,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":4},"100612936","phase-1-immune-cell-therapy-for-advanced-solid-tumors-100612936","NCT07260058","Immune Cell Therapy for Advanced Solid Tumors","Clinical Study on the Safety and Efficacy of Autologous Immune Cell Therapy for Advanced Solid Tumors","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. The participant must voluntarily participate in the study and provide written informed consent。\n2. Age ≥ 18 years, male or female.\n3. Histologically and\u002For cytologically confirmed locally advanced or metastatic solid tumor: lung cancer, liver cancer, colorectal cancer, or breast cancer.\n4. ECOG (Eastern Cooperative Oncology Group) performance status score ≤ 2.\n5. Life expectancy ≥ 3 months.\n6. Has not received any other cellular immunotherapy within 3 months prior to enrollment.\n7. Has at least one measurable lesion according to RECIST (Response Evaluation Criteria in Solid Tumors) Version 1.1.\n8. Adequate organ function, defined as follows:\n\nHematology:\n\nWhite Blood Cell (WBC) count \\> 3.5 × 10⁹\u002FL Lymphocyte count \\> 0.9 × 10⁹\u002FL Monocyte count \\> 0.16 × 10⁹\u002FL Absolute Neutrophil Count (ANC) \\> 1.5 × 10⁹\u002FL Platelet (PLT) count \\> 75 × 10⁹\u002FL Hemoglobin (HB) \\> 75 g\u002FL Blood Biochemistry： Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present)\n\nCoagulation:\n\nProthrombin Time (PT) and International Normalized Ratio (INR) ≤ 1.5 × ULN\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Prior receipt of any salvage chemotherapy, implanted intraperitoneal chemotherapy, targeted therapy, or biological immunotherapy (except: patients whose disease progressed more than 6 months after completing adjuvant, neoadjuvant, or radiosensitizing chemotherapy, or more than 1 month after intraperitoneal chemoperfusion\u002Fwash, are eligible, provided chemotherapy-related toxicities have recovered to Grade 1 or below, excluding alopecia).\n2. Major surgical procedure within 4 weeks prior to enrollment, with incomplete recovery from side effects.\n3. History of any active malignancy within 5 years, except for the specific cancer under investigation in this trial and cured localized tumors such as carcinoma in situ of the cervix, basal cell carcinoma of the skin, and prostate carcinoma in situ.\n4. Presence of more than a small amount of pericardial effusion, or uncontrolled pleural or peritoneal effusion, defined as: detectable by physical examination at screening, or requiring therapeutic paracentesis during the screening period.\n5. Inability to tolerate peripheral blood collection due to various reasons (e.g., severe coronary heart disease, inability to establish peripheral venous access).\n6. Severe cardiovascular disease, including uncontrolled hypertension, unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure \\> NYHA (New York Heart Association) Class III, or severe arrhythmia.\n7. Active infection, unexplained fever ≥ 38.5°C within 7 days prior to medication, or baseline white blood cell count \\> 15×10⁹\u002FL; OR any severe acute or chronic infection requiring systemic antibacterial, antifungal, or antiviral therapy at screening (except for active hepatitis).\n8. Any active autoimmune disease or history of autoimmune diseases (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; Patients with vitiligo; Patients with childhood asthma that has completely resolved in adulthood without any intervention are eligible; Asthma requiring bronchodilator medical intervention is excluded). Patients are eligible if: they have a history of autoimmune-related hypothyroidism and are on stable thyroid hormone replacement therapy; or have type I diabetes controlled by insulin therapy.\n9. History of drug allergy.\n10. Pregnant or lactating women; OR women of childbearing potential or men with pregnant partners who are unwilling to use adequate contraception during the planned trial period (from the screening visit until 120 days after the last study treatment).\n11. History of organ transplantation.\n12. Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.",{"count":292,"type":20},48,[50,23],"The autologous immune cell induction technology used in this project involves transforming peripheral blood mononuclear cells (PBMC) into autologous DC cells, NK cells, CIK cells and other immune cells through cytokine induction, and then re-administering them to the patients. This therapy utilizes biotechnology to culture the immune cells of cancer patients in vitro and then re-infuse them back into the body, stimulating and enhancing the body's own immune function, killing and inhibiting cancer cells, eliminating small and residual lesions, or achieving the goal of treating cancer by significantly inhibiting the proliferation of residual cancer cells.",[296,270,297,26,298],"Lung Cancer (Locally Advanced or Metastatic)","Colorectal Cancer (Locally Advanced or Metastatic)","Advanced Solid Tumors",[298,300,301,302,303,304,305,306,307],"Metastatic Lung Cancer","Metastatic Liver Cancer","Metastatic Colorectal Cancer","Metastatic Breast Cancer","Autologous Immune Cell Therapy","Dendritic Cell Vaccine","CIK Cells","NK Cells","2025-11-20",{"date":310,"type":31},"2025-12-02",{"date":312,"type":20},"2025-12-01",{"date":314,"type":20},"2027-12-31",{"name":316,"class":38},"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd."]